Skip to main content

Advertisement

SpringerLink
Log in

Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Angiogenesis has been highlighted as a critical component in the progression of multiple myeloma (MM), and vascular endothelial growth factor (VEGF) as well as its type 2 receptor (VEGFR2) are thought to play a major role in the process. Single nucleotide polymorphisms (SNPs) have been described in VEGF and VEGFR2 genes, with quantitative or qualitative changes in encoded VEGF and VEGFR2. The roles of VEGF −2578C/A, −1154G/A, and −634G/C as well as VEGFR2 −604T/C and +1192G/A SNPs in the risk and manifestations of MM are still unknown; therefore, this study aimed to clarify this issue. DNA from 192 patients and 209 controls were analyzed by real-time polymerase chain reaction for identification of genotypes. The frequencies of VEGF −2578CC, VEGF −2578CC plus VEGF −634GG, and VEGF −2578CC plus VEGF −1154GG plus VEGF −634GG genotypes were higher in patients than in controls. Carriers of the respective genotypes had a 1.89-, a 5.52-, and a 4.91-fold increased risk for MM than others. VEGF −2578CC plus VEGFR2 +1192GG, VEGF −2578CC plus VEGF −634GG plus VEGFR2 +1192GG, and VEGF −1154GG plus VEGF −634GG plus VEGFR2 −604TT combined genotypes were more common in patients than in controls. Carriers of the respective genotypes had a 2.56-, a 10.97-, and a 14.10-fold increased risk for MM than others. An excess of VEGFR2 −604TT genotype was also seen in patients with stage II or III tumors when compared with those with stage I tumors. Our data suggest, for the first time, that inherited abnormalities in VEGF and VEGFR2 pathways influence the risk and aggressiveness of MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Moehler TM, Neben K, Ho AD, Goldschmidt H (2001) Angiogenesis in hematologic malignancies. Ann Hematol 80(12):695–705

    Article  CAS  PubMed  Google Scholar 

  2. Giuliani N, Storti P, Bolzoni M, Palma BD, Bonomini S (2011) Angiogenesis and multiple myeloma. Cancer Microenviron 4(3):325–337

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Gille H, Kowalski J, Li B, Le Couter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). J Biol Chem 276(5):3222–3230

    Article  CAS  PubMed  Google Scholar 

  4. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950–1961

    Article  CAS  PubMed  Google Scholar 

  5. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV (2003) Expression of VEGF and its receptors by myeloma cells. Leukemia 17(10):2025–2031

    Article  CAS  PubMed  Google Scholar 

  6. Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D (2003) Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 17(10):1961–1966

    Article  CAS  PubMed  Google Scholar 

  7. Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95(8):2630–2636

    CAS  PubMed  Google Scholar 

  8. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV (1999) Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60(12):1245–1249

    Article  CAS  PubMed  Google Scholar 

  9. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232–1235

    Article  CAS  PubMed  Google Scholar 

  10. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, Harden PN (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13(1):260–264

    CAS  PubMed  Google Scholar 

  11. Steffensen KD, Waldsstrom M, Brandslund I, Jakobsen A (2010) The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 117(1):109–116

    Article  CAS  PubMed  Google Scholar 

  12. Kariyazono H, Ohno T, Khajoee V, Ihara K, Kusuhara K, Kinukawa N, Mizuno Y, Hara T (2004) Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 56(6):953–959

    Article  CAS  PubMed  Google Scholar 

  13. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R (2007) Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 50(8):760–767

    Article  CAS  PubMed  Google Scholar 

  14. Belon AP, Barros MB (2011) Life expectancy at birth: impact of variation in mortality by age group and cause of death in Campinas, São Paulo State. Brazil Cad Saude Publica 27(5):877–887

    Article  Google Scholar 

  15. Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1):3–9

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36(3):842–854

    Article  CAS  PubMed  Google Scholar 

  17. Kämmerer PW, Toyoshima T, Eletr S, Kämmerer P, Kuhr K, Al-Nawas B, Brieger J (2010) Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinoma. J Oral Pathol Med 39(10):786–792

    Article  PubMed  Google Scholar 

  18. Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56(2):167–173

    Article  CAS  PubMed  Google Scholar 

  19. Chen H, Wang W, Xingjie Z, Song X, Fan W, Keke Z, Chen G, Zhao Y, Mao Y, Lu D (2012) Association between genetic variations of vascular endothelial growth factor receptor 2 and glioma in the Chinese Han population. J Mol Neurosci 47(3):448–457

    Article  CAS  PubMed  Google Scholar 

  20. Jang MJ, Jeon YJ, Kim JW, Cho YK, Lee SK, Hwang SG, Oh D, Kim NK (2013) Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans. Mol Carcinog 52(1):60–69

    Article  Google Scholar 

  21. Lin L, Cao K, Chen W, Pan X, Zhao H (2013) Four common vascular endothelial growth factor polymorphisms (−2578C > A, −460C > T, +936C > T, and +405G > C) in susceptibility to lung cancer: a meta-analysis. PLoS One 8(10):e75123

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Galimberti S, Nagy B, Palumbo GA, Ciancia E, Buda G, Orciuolo E, Melosi A, Lambelet P, Ronca F, Petrini (2010) Vascular endothelial growth factor polymorphisms in mantle cell lymphoma. Acta Haematol 123(2):91–95

    Article  CAS  PubMed  Google Scholar 

  23. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027

    Article  CAS  PubMed  Google Scholar 

  24. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES (2011) High-resolution haplotype structure in the human genome. Nat Genet 29(2):229–232

    Article  Google Scholar 

  25. Niemöller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O, Possinger K, Sezer O (2003) Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 129(4):234–238

    PubMed  Google Scholar 

  26. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6(8):3111–3116

    CAS  PubMed  Google Scholar 

  27. Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ (2012) Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer 131(5):E636–E642

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no competing interests.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil

    Angelo Borsarelli Carvalho Brito, Gustavo Jacob Lourenço, Gislaine Borba Oliveira, Cármino Antônio De Souza & Carmen Silvia Passos Lima

  2. Department of Pathology, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil

    José Vassallo

Authors
  1. Angelo Borsarelli Carvalho Brito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gustavo Jacob Lourenço
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gislaine Borba Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cármino Antônio De Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. José Vassallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carmen Silvia Passos Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Silvia Passos Lima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brito, A.B.C., Lourenço, G.J., Oliveira, G.B. et al. Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma. Ann Hematol 93, 1363–1369 (2014). https://doi.org/10.1007/s00277-014-2062-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2062-8

Keywords

Search

Navigation